---
title: "BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296376333.md"
description: "BioMarin will acquire Alesta Therapeutics for $275 million upfront, bolstering BioMarin's unit focused on rare skeletal conditions."
datetime: "2026-08-19T15:32:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296376333.md)
  - [en](https://longbridge.com/en/news/296376333.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296376333.md)
generator: "portal-rs"
---

# BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment

BioMarin will acquire Alesta Therapeutics for $275 million upfront, bolstering BioMarin's unit focused on rare skeletal conditions.

### Related Stocks

- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)

## Related News & Research

- [Biomarin To Acquire Alesta Therapeutics To Gain Ale1, A Potential First Oral Therapy For Hypophosphatasia](https://longbridge.com/en/news/296228796.md)
- [BioMarin spends up to $490m for Alesta’s bone disease candidate](https://longbridge.com/en/news/296381315.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)
- [Persistent Asset Partners Ltd Makes New $4.57 Million Investment in BioMarin Pharmaceutical Inc. $BMRN](https://longbridge.com/en/news/296092450.md)
- [Workday stock is downgraded after buyout report as growth expectations are 'too optimistic'](https://longbridge.com/en/news/296104750.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**